Yukin Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Out of Business

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Out of Business

Yukin Therapeutics General Information

Description

Developer of a proprietary therapeutic molecule designed to offer therapeutic molecules for cancer treatment. The company's molecules change the tumour microenvironment to allow the immune system to infiltrate and destroy the tumor effectively to boost existing cancer immunotherapies, enabling doctors to effectively treat several types of cancer, including skin and pancreatic cancers.

Contact Information

Website
www.yukintx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 291 rue Albert Caquot
  • 06560 Sophia Antipolis
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 291 rue Albert Caquot
  • 06560 Sophia Antipolis
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yukin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 06-Dec-2024 Completed Out of Business
3. Early Stage VC 09-Feb-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 15-Mar-2019 $3.73M $3.73M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Yukin Therapeutics’s complete valuation and funding history, request access »

Yukin Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
ABSA Shares
To view Yukin Therapeutics’s complete cap table history, request access »

Yukin Therapeutics Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Yukin Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4169904-A1 Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors Inactive 25-Oct-2021
US-20250026722-A1 Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors Pending 25-Oct-2021
WO-2023072962-A1 Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors Inactive 25-Oct-2021 C07D215/44

Yukin Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Yukin Therapeutics FAQs

  • When was Yukin Therapeutics founded?

    Yukin Therapeutics was founded in 2018.

  • Where is Yukin Therapeutics headquartered?

    Yukin Therapeutics is headquartered in Sophia Antipolis, France.

  • What is the size of Yukin Therapeutics?

    Yukin Therapeutics has 5 total employees.

  • What industry is Yukin Therapeutics in?

    Yukin Therapeutics’s primary industry is Drug Discovery.

  • Is Yukin Therapeutics a private or public company?

    Yukin Therapeutics is a Private company.

  • What is Yukin Therapeutics’s current revenue?

    The current revenue for Yukin Therapeutics is .

  • How much funding has Yukin Therapeutics raised over time?

    Yukin Therapeutics has raised $5.55M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process